On June 4, 2021, jointly organized by the Cell Therapy Research and Application Branch of the Chinese Society for Cell Biology and Shanghai Zhangjiang (Group) Co., LTD., The "2021 Zhangjiang Cell Industry International Summit and the Second Annual Conference of Chinese Cell Therapy" jointly organized by Shanghai University of Science and Technology (Institute of Immunochemistry), Huashan Hospital Affiliated to Fudan University and Shanghai International Medical Park Group Co., Ltd. opened in Zhangjiang Science City.
Zhang Wenhong, director of the Infection Department of Huashan Hospital, came to the scene and exchanged views with participants on the current vaccination and treatment of COVID-19.
Figure | huashan hospital infection of wen-hong zhang
Regarding the topics of the conference, Zhang Wenhong said that stem cells are an emerging field and they have a good prospect for the novel coronavirus pandemic as cell therapy. However, the value of stem cell therapy should extend beyond COVID-19 to severe pneumonia, and the indications for stem cell therapy should be expanded in the future.
"Stem cells can reduce inflammation and repair cells, and all the current research on stem cells in COVID-19 treatment will have a huge impact in the future, but it doesn't mean that COVID-19 treatment can't leave them alone," "The role of pulmonary fibrosis in the repair of lung cells is not only reflected in the novel coronavirus, but should have an effect on all severe pneumonia and pulmonary fibrosis," Zhang said.
